• Three FlexiPro™ Chrom systems to be installed soon at INITS SMO bioproduction site
• The chromatography systems will optimize INITS SMO production processes, ensuring quality and efficiency
• This partnership enhances INITS SMO capacity to meet the growing demands of the biopharmaceutical sector.

Riom, Montpellier, France – INITS SMO, a company specializing in pharmaceutical development and the production of biological products, announced its partnership with VERDOT^®, a leader in purification technologies, to equip its state-of-the-art modular bioproduction unit located near Montpellier. This partnership marks a key milestone in both companies’ commitment to providing sustainable and accessible biotechnological solutions.

The production unit will be equipped with three single-use FlexiPro Chrom chromatography systems from VERDOT, renowned for their flexibility, precision, and operational efficiency. These systems will enable INITS SMO to ensure optimal quality, tailored to the needs of the bioprocessing market.

‘’We are delighted to collaborate with VERDOT, a recognized leader in biological product purification solutions,’’ said Amel Hadri, CEO of INITS. ‘’Their expertise and advanced technologies will strengthen our ability to meet our clients’ growing needs in the field of biotechnology.’’

This partnership perfectly reflects VERDOT’s mission: to support clients with solutions designed to tackle specific and complex challenges. This approach is rooted in expertise and a deep understanding of the diverse and evolving needs of the biopharmaceutical production industry.

Charles Ruban, President and CEO of VERDOT, added: ‘’The FlexiPro Chrom systems we are supplying to INITS SMO are designed for exceptional adaptability. They offer unmatched flexibility and precision, making them perfectly suited to the varied and evolving needs of biopharmaceutical production.’’

With the FlexiPro Chrom systems, VERDOT reaffirms its commitment to innovation and sustainability, offering remarkable adaptability to support the rapid evolution of industrial requirements. These solutions help reduce time-to-market, making biological therapies more accessible and affordable.

A Partnership Built on Shared Values

Both companies share an ambitious vision: to integrate sustainable, modular, and technologically advanced bioproduction solutions within a collaborative framework. While INITS SMO focuses on an innovative model with its shared bioproduction factory concept, VERDOT brings over 70 years of expertise in bioprocessing to meet the most complex demands of biotechnology.

This partnership also reflects a shared commitment to environmentally friendly practices, further enhancing both companies’ ability to offer eco-responsible solutions aligned with current expectations in the biopharmaceutical industry.

 About VERDOT

VERDOT, established in 1950 and headquartered in Riom, France, stands at the forefront of downstream bioprocessing technology. VERDOT focuses on innovative purification solutions for the biopharmaceutical industry, including chromatography columns, and custom and standardized chromatography and tangential flow filtration (TFF) systems. VERDOT systems and columns are employed in the purification, separation and concentration of biomolecules such as monoclonal antibodies, vaccines, viral vectors (e.g., AAV and lentivirus), and mRNA-based therapeutics.

VERDOT serves a diverse customer base, including research and development, early-stage biotech, biopharma, and contract development and manufacturing organizations (CDMOs) in all stages of the drug development workflow from exploration through the manufacturing of commercially available biologics. VERDOT’s tailored, high-quality purification technologies empower their customers to accelerate time-to-market of groundbreaking and cost-effective therapies.

For more information about VERDOT, visit www.verdot-biotechnologies.com

About INITS

Founded in 2013 by Amel Hadri (CEO) and based in Montpellier, France, INITS is a consultancy firm supporting biotech companies in France and internationally.

With a team of 26 passionate experts dedicated to their projects, INITS has always dared to adopt different and disruptive approaches.

INITS supports its clients across the entire pharmaceutical development chain for biological drugs (gene and cell therapy products, exosomes, monoclonal antibodies, etc.), covering areas such as CMC (Chemistry Manufacturing and Controls), IMP (Investigational Medicinal Products), Regulatory Affairs, Quality Assurance, and Audits.

In response to the evolving needs of biotech companies, INITS has been working for three years on implementing an innovative bioproduction services concept: INITS SMO (Shared Manufacturing Organization). This groundbreaking approach to bioproduction will allow biotech companies to implement their innovative processes and conduct GMP productions themselves with INITS’ support.

For more information about INITS, visit https://inits.fr.